Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;93(2):854-862.
doi: 10.1002/jmv.26315. Epub 2020 Oct 5.

Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study

Xiulan Liu  1 , Yi Liu  1 , Keliang Chen  2 , Suying Yan  3 , Xiangrong Bai  3 , Juan Li  1 , Dong Liu  1
Affiliations

Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study

Xiulan Liu et al. J Med Virol. 2021 Feb.

Abstract

To evaluate the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) vs calcium channel blockers (CCBs) on the progression of Corona Virus Disease 2019 (COVID-19) patients with hypertension in Wuhan. This retrospective single-center case series analyzed COVID-19 patients with hypertension, treated with ACEIs/ARBs or CCBs at the Tongji Hospital of Wuhan City, China from 25th January to 15th March 2020. After propensity score matching analysis, 76 patients were selected into two groups. Univariate and multivariable analyses were conducted to determine factors related to improvement measures and outcome measures by Cox proportional hazard regression models. Among 157 patients with confirmed COVID-19 combined hypertension, including 73 males and 84 females, a median age of 67.28 ± 9.11 vs 65.39 ± 10.85 years. A univariable analysis indicated that clinical classification, lymphocyte count, and interleukin-2 receptor were associated with a lengthened negative time of nucleic acid, with a significant difference between two groups (P = .036). Furthermore, we found no obvious difference in nucleic acid conversion time between ACEIs/ARBs and CCBs groups (hazard ratio [HR]: 0.70; 95% confidence interval [CI]: [0.97, 3.38]; P = .18) in the multivariable analysis as well as chest computed tomography improved time (HR: 0.73; 95% CI [0.45, 1.2]; P = .87), and hospitalization time between ACEIs/ARBs and CCBs groups (HR: 1.06; 95% CI [0.44, 1.1]; P = .83). Our study provided additional evidence of no obvious difference in progress and prognosis between ACEIs/ACEIs and CCBs group, which may suggest ACEIs/ARBs may have scarcely influence on increasing the clinical severe situations of COVID-19 patients with hypertension.

Keywords: ACEIs; ARBs; CCBs; COVID-19; RAS blockers; hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
Flow‐chart for patient selection
Figure 2
Figure 2
A, Cox regression analysis curve of nucleic acid conversion time of COVID‐19 patients with hypertension (after PSM). B, Cox regression analysis curve of chest CT improved time of COVID‐19 patients with hypertension (after PSM). C, Cox regression analysis curve of the hospitalization time of COVID‐19 patients with hypertension (after PSM). CT, computed tomography; PSM, propensity score matching
See this image and copyright information in PMC

References

    1. Novel Coronavirus (2019‐nCoV) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio.... Accessed April 6, 2020.
    1. Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID‐19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145‐151. - PubMed
    1. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is there an association between COVID‐19 mortality and the renin‐angiotensin system—a call for epidemiologic investigations. Clin Infect Dis. 2020;71:870‐874. 10.1093/cid/ciaa329 - DOI - PMC - PubMed
    1. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China: Life Sci. 2020;63(3):457‐460. - PMC - PubMed
    1. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin‐converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin‐converting enzyme 2. Circulation. 2005;111(20):2605‐2610. - PubMed

Substances